Proceeds from divestiture of businesses Proceeds from Divestiture of Businesses Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Range [Domain] Statistical Measurement [Domain] Available-for-sale Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Award Timing Predetermined Award Timing Predetermined [Flag] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Asset Class [Axis] Asset Class [Axis] Entity File Number Entity File Number Additional Paid-In Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Net proceeds from sale of future royalties Net proceeds from sale of future royalties Net proceeds from sale of future royalties Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic net loss per common share (in usd per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Revenue, remaining performance obligation, variable consideration amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Net Sales Milestone Net Sales Milestone [Member] Net Sales Milestone Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Inventory Disclosure [Abstract] Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Adjustment to Compensation, Amount Adjustment to Compensation Amount Other non current assets Increase (Decrease) in Other Operating Assets Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Employee Stock Option Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total stockholders' equity Equity, Attributable to Parent Measurement Frequency [Axis] Measurement Frequency [Axis] Insider Trading Policies and Procedures [Line Items] Stock-based compensation expense Share-Based Payment Arrangement, Expense Common stock, shares authorized (in shares) Common Stock, Shares Authorized Liability related to future royalties Liability related to future royalties - beginning balance Liability related to future royalties - ending balance Liability related to future royalties Liability related to future royalties Current assets: Assets, Current [Abstract] Shares, Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders' equity Liabilities and Equity Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Fair Value Measurements, Recurring Basis Fair Value, Recurring [Member] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Royalty revenue RevenueFromRoyalityAgreementsMember [Member] RevenueFromRoyalityAgreementsMember Cover [Abstract] RevenuesFromCMOAgreementsMember RevenuesFromCMOAgreementsMember [Member] RevenuesFromCMOAgreementsMember Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Common Stock Shares Issued Not Disclosed Common Stock Shares Issued Not Disclosed Common Stock Shares Issued Not Disclosed Maximum Maximum [Member] Weighted- Average Exercise Price, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price General and Administrative General and Administrative Expense [Member] Accounting Policies [Abstract] Potential additional post=closing cash payments Disposal Group, Including Discontinued Operation, Contingent Consideration Disposal Group, Including Discontinued Operation, Contingent Consideration Non-refundable upfront payment NonRefundableUpfrontFees Reclassifications Reclassifications [Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Regulatory And Commerical Milestones Regulatory And Commerical Milestones [Member] Regulatory And Commerical Milestones Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Shell Company Entity Shell Company Other non current liabilities Other Liabilities, Noncurrent Proceeds from stock option exercises and ESPP purchases ProceedsfromStockOptionsExercisedAndESPPPurchases Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Other non current liabilities Increase (Decrease) in Other Noncurrent Liabilities Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Weighted- Average Exercise Price, Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Disposal Group Name [Domain] Disposal Group Name [Domain] Name Measure Name Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Lease liabilities Operating Lease, Liability, Current Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] Award Type [Axis] Award Type [Axis] Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Total assets Assets Collaboration And Other Agreements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Potential development and regulatory milestone payments under agreement PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement Contract manufacturing Contract Manufacturing [Member] Contract Manufacturing Trading Symbol Trading Symbol Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Milestone Type [Axis] Milestone Type [Axis] Milestone Type 2022 Gilead Collaboration And License Agreement 2022 Gilead Collaboration And License Agreement [Member] 2022 Gilead Collaboration And License Agreement Entity Address, City or Town Entity Address, City or Town Cash flows from operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Other segment income (loss), net Segment Reporting, Other Segment Item, Amount Inventory, Net Inventory Disclosure [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Restricted Stock Units Restricted Stock Units (RSUs) [Member] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Offering period Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period Assets: Assets, Fair Value Disclosure [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Shares, Outstanding, Beginning Balance (in shares) Shares, Outstanding, Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Collaborative and other agreements RevenueFromCollaborativeAgreementsMember Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Plan Name [Axis] Plan Name [Axis] Liability Related to Future Royalty Liability Related to Future Royalty [Table Text Block] Liability Related to Future Royalty PEO PEO [Member] Cost of manufacturing services Cost of manufacturing services Cost of manufacturing services Non-cash operating and investing activities Noncash Investing and Financing Items [Abstract] Common stock purchased (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Incyte Commercial Supply Agreement Incyte Commercial Supply Agreement [Member] Incyte Commercial Supply Agreement Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-Based Payment Arrangement [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Development and regulatory milestones recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Synaffix B.V. Synaffix B.V. [Member] Synaffix B.V. Deferred transaction costs Deferred transaction costs Deferred transaction costs Deferred transaction costs 2016 Employee Stock Purchase Plan TwoThousandSixteenEmployeeStockPurchasePlanMember Accumulated other comprehensive (loss) income AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cash received for options exercised Proceeds from Stock Options Exercised City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Interest and other income Other Nonoperating Income All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Sanofi S.A. Sanofi S.A. [Member] Sanofi S.A. Weighted- Average Remaining Contractual Term, Vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Accrued expenses and other current liabilities Accrued Liabilities, Current Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Incyte Corporation IncyteCorporationMember Commitments and Contingencies Disclosure [Abstract] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Non-cash lease expense Operating Lease, Noncash Expense Operating Lease, Noncash Expense Cash flows from investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] General and administrative General and Administrative Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Schedule of Stock Options Roll Forward Schedule of Stock Options Roll Forward [Table Text Block] Subsequent Event Subsequent Event [Member] Valuation Assumptions Using the Black-Scholes Option-Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Gilead First Research Program Gilead First Research Program [Member] Gilead First Research Program Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Money market funds Money Market Funds [Member] Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Equity Components [Axis] Equity Components [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Number of reportable segments Number of Reportable Segments Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Non-cash interest expense recognized Non-cash interest expense recognized Non-cash interest expense recognized Annual Fixed Payments Total Annual Fixed Payments Total Annual Fixed Payments Bora Purchase Agreement Bora Purchase Agreement [Member] Bora Purchase Agreement Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other Performance Measure, Amount Other Performance Measure, Amount Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Address, State or Province Entity Address, State or Province Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current TwoThousandSixteenEmployeeStockPurchasePlanMember TwoThousandSixteenEmployeeStockPurchasePlanMember [Member] TwoThousandSixteenEmployeeStockPurchasePlanMember Individual: Individual [Axis] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Additional Payments Additional Annual Fixed Payments Additional Annual Fixed Payments Research and Development Research and Development Expense [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Revenue, remaining performance obligation, expected timing of satisfaction Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Project [Domain] Project [Domain] Right-of-use asset Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] ADC ADC [Member] Preclinical antibody-drug conjugates Entity Interactive Data Current Entity Interactive Data Current Plan Name [Domain] Plan Name [Domain] Vobramitanmab duocarmazine Vobramitanmab duocarmazine [Member] Vobramitanmab duocarmazine Unrecognized compensation expense recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Shares, Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Segment Reporting Disclosure Segment Reporting Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] U.S. Treasury securities US Treasury Securities [Member] Royalty Monetization Arrangement Royalty Monetization Arrangement [Member] Royalty Monetization Arrangement Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Royalty payment threshold Royalty Monetization Arrangement, Royalty Payment Threshold Royalty Monetization Arrangement, Royalty Payment Threshold Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Collaborative agreement transaction price CollaborativeAgreementTransactionPrice Depreciation and amortization Depreciation, Depletion and Amortization Other non current assets Other Assets, Noncurrent Stock plan related activity Stock Issued During Period Value Stock Plan Activity Value of shares issued due to stock plan related activity. Entity Central Index Key Entity Central Index Key PEO Name PEO Name Total revenues Revenues Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount In-Licensing arrangement [Line Items] In-Licensing arrangement [Line Items] In-Licensing arrangement [Line Items] Gilead Second Research Program Gilead Second Research Program [Member] Gilead Second Research Program Arrangement Duration Trading Arrangement Duration Deferred revenue Deferred revenue, current Contract with Customer, Liability, Current Segments [Axis] Segments [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Liability related to future royalty [Table] Liability related to future royalty [Table] Liability related to future royalty [Table] Assets Assets [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Extension term Revenue, Performance Obligation, Extension Term Revenue, Performance Obligation, Extension Term Stockholders' equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Research and development Research and Development Expense Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Liability related to future royalties [Roll Forward] Liability related to future royalties [Roll Forward] Liability related to future royalties Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Disposal Group, Held-for-Sale, Not Discontinued Operations Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period MGD024 MGD024 [Member] MGD024 Total costs and expenses Costs and Expenses Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount 2025 Agreement 2025 Agreement [Member] 2025 Agreement Document Quarterly Report Document Quarterly Report Total assets measured at fair value Assets, Fair Value Disclosure Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Number of operating segments Number of Operating Segments Potential commercial milestone payments under agreement PotentialCommercialMilestonePaymentsUnderAgreement Government-sponsored enterprises US Government-sponsored Enterprises Debt Securities [Member] Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Weighted- Average Remaining Contractual Term, Outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Marketable securities Investments Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Non-PEO NEO Non-PEO NEO [Member] Aggregate Intrinsic Value, Outstanding, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Allowance for credit loss related to available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Manufacturing Services Manufacturing Services [Member] Manufacturing Services Potential proceeds from royalties (percent) ProceedsfromRoyaltiesPercent Aggregate purchase price multiple, maximum Royalty Monetization Arrangement, Aggregate Purchase Price Multiple, Maximum Royalty Monetization Arrangement, Aggregate Purchase Price Multiple, Maximum Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name Award Type [Domain] Award Type [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Liability related to future royalty [Line Items] Liability related to future royalty [Line Items] Liability related to future royalty [Line Items] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Recovery of Erroneously Awarded Compensation Disclosure [Line Items] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Incyte MGA012 Agreement IncyteMGA012AgreementMember Revenues: Revenues [Abstract] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Aggregate Intrinsic Value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Financial Instruments [Domain] Financial Instruments [Domain] Unrealized loss on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Accumulated Other Comprehensive Income (Loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Segments [Domain] Segments [Domain] Royalty Monetization Arrangement Liability Related To Sale Of Future Royalties [Text Block] Liability Related To Sale Of Future Royalties Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Main Segment Main Segment [Member] Reportable segment, which is discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Royalty Royalty [Member] Other programs Other programs [Member] Other programs Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Inventory Increase (Decrease) in Inventories Inventory, net Inventory, Net Minimum Minimum [Member] Company Selected Measure Name Company Selected Measure Name Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Common stock, $0.01 par value -- 125,000,000 shares authorized, 63,560,068 and 63,318,613 shares outstanding at March 31, 2026 and December 31, 2025, respectively Common Stock, Value, Issued In-licensing arrangement Commitments and Contingencies Disclosure [Text Block] Diluted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Stock Options And Restricted Stock Units Stock Options And Restricted Stock Units [Member] Stock Options And Restricted Stock Units Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Small Business Entity Small Business Document Transition Report Document Transition Report Net loss per common share: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Agreement [Domain] Agreement [Domain] Agreement [Domain] Underlying Securities Award Underlying Securities Amount Stock plan activity (in shares) Stock Issued During Period Shares Stock Plan Activity Number of shares issued due to stock plan related activity. Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Project [Axis] Project [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Contractual Obligation Contractual Obligation Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from Contract with Customer [Abstract] Scenario [Axis] Scenario [Axis] Weighted- Average Remaining Contractual Term, Exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Asset Purchase Agreement Asset Purchase Agreement [Member] Asset Acquisition Agreement Lease liabilities Increase (Decrease) in Operating Lease Liability Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Document Type Document Type Contingent payment receivable Royalty Monetization Arrangement, Contingent Payment Receivable Royalty Monetization Arrangement, Contingent Payment Receivable Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Product and Service [Axis] Product and Service [Axis] Next-generation T-cell engagers Next-generation T-cell engagers [Member] Next-generation T-cell engagers All Individuals All Individuals [Member] Gilead Gilead [Member] Gilead Fair Value Disclosures [Abstract] Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment Shares, Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number RevenuesFromCMOAmendmentAgreement RevenuesFromCMOAmendmentAgreement [Member] RevenuesFromCMOAmendmentAgreement Name Forgone Recovery, Individual Name Emergent Biosolutions Emergent Biosolutions [Member] Emergent Biosolutions Total current assets Assets, Current Range [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Disposal Group Name [Axis] Disposal Group Name [Axis] Purchase price of common stock percent of the fair market value Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] 2022 Agreement 2022 Agreement [Member] 2022 Agreement Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Current liabilities: Liabilities, Current [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Level 1 Fair Value, Inputs, Level 1 [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Revenue Collaboration And Other Agreements Disclosure [Text Block] Lorigerlimab Lorigerlimab [Member] Lorigerlimab StockIncentivePlan2023Member StockIncentivePlan2023Member [Member] StockIncentivePlan2023Member Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Diluted net loss per common share (in usd per share) Earnings Per Share, Diluted Forecast Forecast [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Title of 12(b) Security Title of 12(b) Security Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Liability related to future royalties [Abstract] Liability related to future royalties [Abstract] Liability related to future royalties [Abstract] Earnings Per Share [Abstract] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Investments, Debt and Equity Securities [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Proceeds from sale of future royalties Proceeds from sale of future royalties Proceeds from sale of future royalties Deferred revenue Increase (Decrease) in Contract with Customer, Liability Number of product candidates approved by the FDA Number Of Product Candidates Approved By The Food And Drug Administration Number Of Product Candidates Approved By The Food And Drug Administration Revenue, remaining performance obligation, variable consideration, royalty percentage Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage Weighted- Average Exercise Price, Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price License And Collaboration Agreements [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Weighted- Average Exercise Price, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Aggregate purchase price multiple, minimum Royalty Monetization Arrangement, Aggregate Purchase Price Multiple, Minimum Royalty Monetization Arrangement, Aggregate Purchase Price Multiple, Minimum Subsequent Event [Table] Subsequent Event [Table] Expiration Date Trading Arrangement Expiration Date Agreement [Axis] Agreement [Axis] Agreement Property, equipment and software, net Property, Plant and Equipment, Net Non-cash royalty revenue Royalty Income, Nonoperating Adoption Date Trading Arrangement Adoption Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Entity Current Reporting Status Entity Current Reporting Status Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Loss from operations Operating Income (Loss) Accumulated deficit Retained Earnings (Accumulated Deficit) Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Accounts payable Increase (Decrease) in Accounts Payable and Other Operating Liabilities Shares, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Interest and other expense Interest Expense, Operating and Nonoperating Current Fiscal Year End Date Current Fiscal Year End Date Subsequent Event Type [Domain] Subsequent Event Type [Domain] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Stock Option Additional Information [Table] Stock Option Additional Information [Table Text Block] Stock Option Additional Information Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] In-licensing arrangement[Table] In-Licensing arrangement [Table] In-Licensing arrangement Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Statement [Table] Statement [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Weighted-average grant-date fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Provention PRV031 Provention PRV031 [Member] Provention PRV031 Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Deferred revenue Contract with Customer, Liability Stock options and RSUs (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Share-based compensation, number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Termination Date Trading Arrangement Termination Date Net cash used in financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Basic weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Sagard Healthcare Partners Sagard Healthcare Partners [Member] Sagard Healthcare Partners Shares, Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Subsequent Events [Abstract] Segment Reporting [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] MGC028 MGC028 [Member] MGC028 Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Entity Tax Identification Number Entity Tax Identification Number Scenario [Domain] Scenario [Domain] Costs and expenses: Costs and Expenses [Abstract] Milestone Type [Domain] Milestone Type [Domain] Milestone Type [Domain] Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share) Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Revenues From License Agreements RevenuesFromLicenseAgreementsMember Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share MGC030 MGC030 [Member] MGC030 Number of performance obligations Number Of Performance Obligations Potential option fees Opt-In Fee Opt-In Fee Variable consideration recognized Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Number of proprietary product candidates advancing in clinical development Number Of Proprietary Product Candidates Advancing In Clinical Development Number Of Proprietary Product Candidates Advancing In Clinical Development Non-cash interest expense recognized Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Financial Assets Measured at Fair Value on a Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Subsequent Event Subsequent Events [Text Block] Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Weighted- Average Exercise Price, Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Property and equipment included in accounts payable or accruals Capital Expenditures Incurred but Not yet Paid Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] MGC026 MGC026 [Member] MGC026 Proceeds from maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Non-cash royalty revenue payable to Sagard Noncash Royalty Revenue Payable Noncash Royalty Revenue Payable Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Asset Class [Domain] Asset Class [Domain] Stock plan related activity Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Subsequent Event [Line Items] Subsequent Event [Line Items] Common Stock Common Stock [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Securities Fair Value Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Corporate debt securities Corporate Debt Securities [Member] Effective interest rate Royalty Monetization Arrangement, Interest Rate, Effective Percentage Royalty Monetization Arrangement, Interest Rate, Effective Percentage Net change in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Potential target nomination, option fees and milestone payments Potential target nomination, option fees and milestone payments Potential target, nomination, option fees and milestone payments Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain]